BioSpace News Archive

These small molecules, known as ISR (Integrated Stress Response) modulators, are oral compounds that selectively prolong the body’s natural protective effect against cellular stress as a way to potentially delay or halt disease progression.

AcuSurgical, a French startup developing novel robots and procedures for the retina and ophthalmology surgery markets, announces the appointment of Michael Brownell as Chairman of the Board.

Vaccination programs aimed at controlling the impact of COVID-19 have proceeded at an unprecedented pace; the positive impact of which is clear when examining case counts in jurisdictions that have seen an efficient immunization rollout.

To drive brand awareness of, and access to, HaluGen’s Psychedelics Genetic Test Kit

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced it has entered into a definitive agreement to acquire Corlieve Therapeutics and its lead program, which will be known as AMT-260, to treat temporal lobe epilepsy, the most common form of focal epilepsy.

uniQure N.V. (NASDAQ: QURE), today announced positive 52-week clinical data on all patients from its pivotal, Phase III HOPE-B gene therapy trial of etranacogene dezaparvovec, an investigational adeno-associated virus five (AAV5)-based gene therapy for the treatment of patients with severe and moderately severe hemophilia B.

Cardiac Insight, Inc. (“Cardiac Insight” or the “Company”) is a healthcare innovator specializing in wearable cardiac sensors and proprietary software that automatically analyzes electrocardiogram (ECG) data to improve early detection and diagnosis of cardiac arrythmias, such as atrial fibrillation (AFib).

Closed Systems Drug Transfer Devices Market: Key Insights

The global atrial fibrillation market is expected to reach US$ 18,085.96 Mn in 2027 from US$ 6,446.08 Mn in 2019.

InMed Pharmaceuticals Inc., a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids, announced that Eric. A. Adams, President and CEO of InMed will present live at LifeSciencesInvestorForum.com on June 24th.